Scientists finally reveal how this Alzheimer’s drug really works

Lecanemab, marketed as Leqembi, is a monoclonal antibody treatment for Alzheimer's disease that targets and removes harmful amyloid plaques while slowing cognitive decline. Scientists from VIB and KU Leuven have now uncovered exactly how it works. Their research shows that a specific part of the antibody, known as the 'Fc fragment', is crucial for activating microglia -- the immune cells of the brain -, which then begin clearing these toxic deposits. This study provides the first c...